| |
| AIM: To investigate screening makers for gastric cancer, we assessed association between gastric cancer with serum pepsinogens in the study.( 19 words) METHODS: From 2008 to 2010, the subjects comprised of 450 patients with gastric cancer, 111 individuals with gastric atrophy, and 961 healthy controls were investigated in a cross section study in the Chinese population. Serum anti-Helicobacter pylori (H.pylori) IgG, pepsinogen (PG)I and PG II were detected by enzyme-linked immunosorbent assay methods (Biohit ELISA kit, Biohit, Helsinki, Finland). Gastric atrophy and gastric cancer were diagnosed by endoscopy and histopatholgical examinations. Odds ratio (ORs) and 95% confidence intervals (CIs) were calculated using a multivariate logistic regression. (82 words) RESULTS: Prevalence rate of H.pylori infection remains high in the Northeastern area of China. Rates of H.pylori IgG positive were greater in the gastric cancer and gastric atrophy groups compared to the control group (69.1%, 75.7% vs 49.7%, P<0.001). Higher level of PG II (15.9, 13.9 vs 11.5, P <0.001) and lower PGI /PGII ratio (5.4, 4.6 vs 8.4, P<0.001) were found in patients with either gastric cancer or gastric atrophy compared to healthy controls, whereas no correlation was found between the plasma PGI concentration and risk of gastric cancer (P=0.537). In addition, multivariate logistic analysis indicates that H.pylori infection and atrophic gastritis were independent risk factors for gastric cancer. Lower plasma PG I: II ratio is associated with higher risks of atrophy and gastric cancer. Furthermore, plasma PG II level significantly correlated with H. pylori-infected gastric cancer. (137 words) CONCLUSION: The serum PG II concentration and PGI/PGII ratio are potential biomarkers for H.pylori-infected gastric disease screening. PG II is independently associated with risk of gastric cancer. |
|
| Keywords:gastric cancer; pepsinogens; Helicobacter pylori; gastric atrophy; screening |
|
